Search for a trial

Dose Reduction of preoperative radiotherapy in myxoid liposarcoma

To study the feasibility of reducing the dose of preoperative radiotherapy in MLS from 50Gy to 36Gy while maintaining comparable clinicopathological responses.

Extent and kind of cognitieve dysfunctions in patients suffering from bipolar disorder: their determinants and impact on clinical and functional outcome

The primary objective is the extent and kind of cognitive deficits in patients suffering from bipolar disorders compared to healthy controls and patients with a lifetime diagnosis of unipolar depressive disorder. Secondary objectives specify the…

A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse

The revised aims of the SORCE trial are:1. Does up to three years of treatment with sorafenib increase DFS compared with placebo: a comparison of Arm C vs Arm A2. If the answer to question (i) is yes, does one year of sorafenib (Arm B) increase DFS…

A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma

*To assess the efficacy of VMP versus high-dose therapy (HDT) and stem cell transplantation in patients with previously untreated multiple myeloma, as measured by the progression free survival.**To evaluate the effect of consolidation with VRD…

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors

Primary: To determine the pharmacokinetics of several clinically used targeted anti-cancer agents.Secondary: To examine the relationship between treatment response/toxicity and plasma (or intracellular) drug levels.To evaluate the specific influence…

Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA)

This study has been transitioned to CTIS with ID 2024-515487-31-00 check the CTIS register for the current data. The primary objective of this study is to describe the pharmacokinetics of antiretroviral agents, for which no or limited available…

Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis

* To investigate the long-term safety and tolerability of ponesimod * To investigate the long-term efficacy of ponesimod* To explore the dose response relationship of 10, 20 and 40 mg ponesimod on lymphocyte count, MRI endpoints and annualized…

Netherlands Epidemiology of Obesity study

Primary general objectives of the NEO study1. To study the pathways that lead to common diseases in overweight and obese individuals.2. To identify novel determinants of various diseases and conditions in overweight and obese individuals.3. To study…

Open-label, multicenter study of the 18F labeled PET/CT (positron emission tomography / computed tomography) tracer BAY 86-9596 following a single intravenous administration of 200 or 300 MBq (corresponding to <= 18 µg mass dose), for evaluation of radiation dosimetry, plasma pharmacokinetics, safety and tolerability in healthy volunteers (200 MBq) as well as investigation of safety, tolerability and diagnostic performance in patients (300 MBq) with non small cell long cancer, breast cancer, hea

Primary objective:Explorative investigation of the tumor detection rate with BAY 86-9596 in comparison to that of 18F-fluorodeoxyglucose (FDG)Secondary objectives:- Determination of radiation dosimetry and pharmacokinetics of BAY 86-9596 in healthy…

Functional analysis of molecular mechanisms underlying parasympathetic regulation of human adipose

To characterize the molecular mechanisms underlying parasympathetic regulation of adipose tissue.

BIOTRONIKS-Safety and Clinical Performance of the First Drug-Eluting Generation Absorbable Metal Stent In Patients with de Novo Lesions in Native Coronary Arteries (BIOSOLVE-I study)

To evaluate safety and clinical performance of the investigation product (drug-eluting absorbable metal stent system)